Abstract
It has become increasingly apparent that current antiangiogenic therapy elicits modest effects in clinical settings. In addition, it remains challenging to treat cancer metastasis through antiangiogenic regimes. Rho GTPases are essential for vascular endothelial growth factor (VEGF)-mediated angiogenesis and are involved in tumour cell invasion. This review discusses novel therapeutic strategies that interfere with Rho GTPase signalling and further explores this network as a target for anticancer therapy through interference with tumour angiogenesis and invasion. Recent findings describe the development of innovative Rho GTPase inhibitors. Positive clinical effects of Rho GTPase targeting in combination with conventional anticancer therapy is of increasing interest.
| Translated title of the contribution | The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. |
|---|---|
| Original language | Undefined/Unknown |
| Pages (from-to) | 219-28 |
| Number of pages | 10 |
| Journal | Drug Discovery Today |
| Volume | 16 |
| Issue number | 5-6 |
| Publication status | Published - 2011 |
Keywords
- Medical technology
- Farmacie(FARM)
- Biomedische technologie en medicijnen
- Pharmacology